Related references
Note: Only part of the references are listed.Residual melanoma in wide local excision specimens after 'complete' excision of primary cutaneous in situ and invasive melanomas
Louise A. Jackett et al.
PATHOLOGY (2022)
Melanoma In Situ: A Critical Review and Re-Evaluation of Current Excision Margin Recommendations
Erica B. Friedman et al.
ADVANCES IN THERAPY (2021)
Estimated risk of progression of lentigo maligna to lentigo maligna melanoma
Scott W. Menzies et al.
MELANOMA RESEARCH (2020)
Strategies for Reducing Final Surgical Defect Sizes in the Treatment of Lentigo Maligna
Blake P. Sampson et al.
DERMATOLOGIC SURGERY (2020)
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019
Claus Garbe et al.
EUROPEAN JOURNAL OF CANCER (2020)
Guidelines of care for the management of primary cutaneous melanoma
Susan M. Swetter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Rate of Recurrence of Lentigo Maligna Treated With Off-label Neoadjuvant Topical Imiquimod, 5%, Cream Prior to Conservatively Staged Excision
Jessica M. Donigan et al.
JAMA DERMATOLOGY (2018)
Comparison of Melanocyte Density Counts in Topical lmiquimod-Treated Skin Surrounding Lentigo Maligna vs Control Biopsy Specimens
Shadai Flores et al.
JAMA DERMATOLOGY (2018)
Clinical factors associated with subclinical spread of in situ melanoma
Thuzar M. Shin et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures
D. Tio et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Effect of topical imiquimod as primary treatment for lentigo maligna: the LIMIT-1 study
J. R. Marsden et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Imiquimod in dermatology: an overview
Edith Hanna et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2016)
A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance
Ariana N. Mora et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
A Randomized Trial of the Off-label Use of Imiquimod, 5%, Cream With vs Without Tazarotene, 0.1%, Gel for the Treatment of Lentigo Maligna, Followed by Conservative Staged Excisions
Mark A. Hyde et al.
ARCHIVES OF DERMATOLOGY (2012)
Efficacy of Imiquimod Cream, 5%, for Lentigo Maligna After Complete Excision A Study of 43 Patients
Lena Ly et al.
ARCHIVES OF DERMATOLOGY (2011)
A pilot study of treatment of lentigo maligna with 5% imiquimod cream
CJ Fleming et al.
BRITISH JOURNAL OF DERMATOLOGY (2004)
Share Paper
